Globus Medical Inc stock (US3795772082): Q1 2026 earnings and guidance in focus after recent price consolidation

Globus Medical Inc shares on the New York Stock Exchange traded around the low-80 USD area in recent sessions, with one quote showing USD 81.88 as of 05/29/2026, as investors in the United States continue to assess the company’s latest quarterly figures and updated guidance for 2026.

The Pennsylvania-based spine and musculoskeletal device specialist reported worldwide net sales of USD 759.9 million for the first quarter of 2026 on 05/07/2026, according to a company earnings release, representing year-on-year growth of 27.0 percent and 25.5 percent on a constant-currency basis.Globus Medical IR as of 05/07/2026

The company generated GAAP net income of USD 124.3 million in Q1 2026 and reported GAAP diluted earnings per share of USD 0.90 alongside non-GAAP diluted EPS of USD 1.12 for the period, based on the same 05/07/2026 earnings announcement.Globus Medical IR as of 05/07/2026

Management reiterated its full-year 2026 revenue outlook in that release, keeping guidance in a range of USD 3.18 billion to USD 3.22 billion, while at the same time lifting its non-GAAP EPS guidance corridor to USD 4.70 to USD 4.80 for 2026, compared with previously communicated expectations that were lower than this updated range.Globus Medical IR as of 05/07/2026

According to one market data snapshot, the trailing earnings per share figure for Globus Medical stands near USD 4.30, translating into a price-to-earnings ratio close to 19 at recent prices, while consensus expectations compiled around late May 2026 point to EPS rising to a range just above USD 4.70 in the coming year.MarketBeat as of 05/29/2026

The stock’s current trading level therefore reflects a balance between the strong reported top-line growth, improved profitability metrics and the integration of prior acquisitions, notably in neuromodulation, which the company cited as contributing to sales momentum and operating leverage in its first-quarter 2026 commentary.Globus Medical IR as of 05/07/2026

The stock is also accessible for investors in Germany through trading venues such as Tradegate, where parallel quotations in euros give an additional point of reference for those following the United States-listed medtech name from the euro area.

As of: 06/01/2026

By the editorial team - specialized in equity coverage.

Globus Medical Inc: core business model

Globus Medical Inc focuses on designing and commercializing spine and musculoskeletal technology platforms, with revenue primarily generated from implantable devices and enabling systems used by surgeons in hospitals and outpatient care settings.

What banks and research houses say about Globus Medical Inc

For the analyst-focused view, aggregated data from one broker consensus source as of 05/29/2026 points to a generally positive stance on Globus Medical, with a consensus rating described as "moderate buy" across 15 Wall Street analysts and an average 12-month price target of USD 106.36, implying potential upside from a reference price of USD 82.00 at the end of May 2026.MarketBeat as of 05/29/2026

Within that same consensus, the highest published target reaches USD 123.00 and the lowest USD 64.00, indicating a relatively broad dispersion of views among covering analysts regarding the pace of integration benefits, competitive dynamics in spine and trauma, and the trajectory of Globus Medical’s profitability over the coming 12 months.MarketBeat as of 05/29/2026

Conclusion

Globus Medical’s latest quarter shows strong double-digit revenue growth, rising earnings and an upward revision to non-GAAP EPS guidance for 2026, while the stock price around the low-80 USD level suggests investors are closely weighing those fundamentals against execution and competition risks in the United States medtech space.

The current analyst consensus, pointing to a moderate buy stance and an average 12-month price objective above the current share price, encapsulates a view that successful integration of acquisitions and continued demand for spine and musculoskeletal solutions could support earnings expansion, although the range of published targets highlights differing assessments of the company’s medium-term potential.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.